• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pulmonary Tuberculosis - Pipeline Review, H2 2013 - Product Image

Pulmonary Tuberculosis - Pipeline Review, H2 2013

  • ID: 2686568
  • October 2013
  • 45 pages
  • Global Markets Direct

Pulmonary Tuberculosis - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Pulmonary Tuberculosis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Tuberculosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Tuberculosis. Pulmonary Tuberculosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pulmonary Tuberculosis.
- A review of the Pulmonary Tuberculosis products under development by companies READ MORE >

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Pulmonary Tuberculosis Overview
Therapeutics Development
An Overview of Pipeline Products for Pulmonary Tuberculosis
Pulmonary Tuberculosis Therapeutics under Development by Companies
Pulmonary Tuberculosis Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Pulmonary Tuberculosis Therapeutics - Products under Development by Companies
Pulmonary Tuberculosis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Pulmonary Tuberculosis Therapeutics Development
Sequella, Inc.
AstraZeneca PLC
Pulmonary Tuberculosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
SQ-109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SQ-609 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sutezolid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
r30 Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD-5847 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PA-824 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BT Compound Inhalation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rBCG30 Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Live Recombinant Booster Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pulmonary Tuberculosis Therapeutics - Drug Profile Updates
Pulmonary Tuberculosis Therapeutics - Dormant Products
Pulmonary Tuberculosis - Product Development Milestones
Featured News & Press Releases
Jul 26, 2013: Otsuka Receives Opinion from CHMP on Delamanid
Jul 02, 2012: Janssen Submits New Drug Application To FDA For Bedaquiline For Multi-Drug Resistant Tuberculosis Treatment
Oct 18, 2010: Sequella Receives International Support For Phase II Clinical Trials Of SQ109 For Treatment Of Adult Pulmonary Tuberculosis
Oct 18, 2005: The Global Alliance for TB Drug Development Announces Phase II Trials To Study Potential Of Moxifloxacin To Shorten TB Treatment Partners Commit To Affordable Pricing For Patients In The Developing World
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Pulmonary Tuberculosis, H2 2013
Products under Development for Pulmonary Tuberculosis - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Sequella, Inc., H2 2013
AstraZeneca PLC, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Pulmonary Tuberculosis Therapeutics - Drug Profile Updates
Pulmonary Tuberculosis Therapeutics - Dormant Products

List of Figures
Number of Products under Development for Pulmonary Tuberculosis, H2 2013
Products under Development for Pulmonary Tuberculosis - Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Discovery and Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013 22

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos